ARTICLE | Clinical News
BGB-A317: Phase I started
July 18, 2016 7:00 AM UTC
BeiGene began an open-label, dose-escalation, dose-expansion, Australian Phase I trial to evaluate IV BGB-A317 every 3 weeks plus oral BGB-3111 in about 25 patients. BeiGene’s BGB-3111 is a selective...